These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 18768519)

  • 1. Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer.
    Lowe KA; Shah C; Wallace E; Anderson G; Paley P; McIntosh M; Andersen MR; Scholler N; Bergan L; Thorpe J; Urban N; Drescher CW
    Cancer Epidemiol Biomarkers Prev; 2008 Sep; 17(9):2480-7. PubMed ID: 18768519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.
    Shah CA; Lowe KA; Paley P; Wallace E; Anderson GL; McIntosh MW; Andersen MR; Scholler N; Bergan LA; Thorpe JD; Urban N; Drescher CW
    Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1365-72. PubMed ID: 19423517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.
    Abdel-Azeez HA; Labib HA; Sharaf SM; Refai AN
    Asian Pac J Cancer Prev; 2010; 11(1):111-6. PubMed ID: 20593939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study.
    Anderson GL; McIntosh M; Wu L; Barnett M; Goodman G; Thorpe JD; Bergan L; Thornquist MD; Scholler N; Kim N; O'Briant K; Drescher C; Urban N
    J Natl Cancer Inst; 2010 Jan; 102(1):26-38. PubMed ID: 20042715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases.
    Molina R; Escudero JM; Augé JM; Filella X; Foj L; Torné A; Lejarcegui J; Pahisa J
    Tumour Biol; 2011 Dec; 32(6):1087-95. PubMed ID: 21863264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential markers that complement expression of CA125 in epithelial ovarian cancer.
    Rosen DG; Wang L; Atkinson JN; Yu Y; Lu KH; Diamandis EP; Hellstrom I; Mok SC; Liu J; Bast RC
    Gynecol Oncol; 2005 Nov; 99(2):267-77. PubMed ID: 16061277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.
    Kadija S; Stefanovic A; Jeremic K; Radojevic MM; Nikolic L; Markovic I; Atanackovic J
    Int J Gynecol Cancer; 2012 Feb; 22(2):238-44. PubMed ID: 22214964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus.
    Moore RG; Brown AK; Miller MC; Badgwell D; Lu Z; Allard WJ; Granai CO; Bast RC; Lu K
    Gynecol Oncol; 2008 Aug; 110(2):196-201. PubMed ID: 18495222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other.
    Hellstrom I; Hellstrom KE
    Adv Exp Med Biol; 2008; 622():15-21. PubMed ID: 18546615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HE4 can help discriminate women with malignant ovarian 
tumors only if CA125 levels are elevated.
    Pitta Dda R; Sarian LO; Campos EA; Andrade LL; Sallum LF; Bragança JF; Campos Cde M; Derchain S
    Int J Biol Markers; 2013; 28(4):e377-86. PubMed ID: 23828407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125.
    Schummer M; Drescher C; Forrest R; Gough S; Thorpe J; Hellström I; Hellström KE; Urban N
    Gynecol Oncol; 2012 Apr; 125(1):65-9. PubMed ID: 22155417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting.
    Jacob F; Meier M; Caduff R; Goldstein D; Pochechueva T; Hacker N; Fink D; Heinzelmann-Schwarz V
    Gynecol Oncol; 2011 Jun; 121(3):487-91. PubMed ID: 21420727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer.
    Andersen MR; Goff BA; Lowe KA; Scholler N; Bergan L; Drescher CW; Paley P; Urban N
    Gynecol Oncol; 2010 Mar; 116(3):378-83. PubMed ID: 19945742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts.
    Huhtinen K; Suvitie P; Hiissa J; Junnila J; Huvila J; Kujari H; Setälä M; Härkki P; Jalkanen J; Fraser J; Mäkinen J; Auranen A; Poutanen M; Perheentupa A
    Br J Cancer; 2009 Apr; 100(8):1315-9. PubMed ID: 19337252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.
    Moore RG; McMeekin DS; Brown AK; DiSilvestro P; Miller MC; Allard WJ; Gajewski W; Kurman R; Bast RC; Skates SJ
    Gynecol Oncol; 2009 Jan; 112(1):40-6. PubMed ID: 18851871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential role of HE4 in multimodal screening for epithelial ovarian cancer.
    Urban N; Thorpe JD; Bergan LA; Forrest RM; Kampani AV; Scholler N; O'Briant KC; Anderson GL; Cramer DW; Berg CD; McIntosh MW; Hartge P; Drescher CW
    J Natl Cancer Inst; 2011 Nov; 103(21):1630-4. PubMed ID: 21917606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?
    Montagnana M; Danese E; Ruzzenente O; Bresciani V; Nuzzo T; Gelati M; Salvagno GL; Franchi M; Lippi G; Guidi GC
    Clin Chem Lab Med; 2011 Mar; 49(3):521-5. PubMed ID: 21288178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases.
    Park Y; Lee JH; Hong DJ; Lee EY; Kim HS
    Clin Biochem; 2011 Jul; 44(10-11):884-8. PubMed ID: 21549107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome.
    Sandri MT; Bottari F; Franchi D; Boveri S; Candiani M; Ronzoni S; Peiretti M; Radice D; Passerini R; Sideri M
    Gynecol Oncol; 2013 Feb; 128(2):233-8. PubMed ID: 23200911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population.
    Kim YM; Whang DH; Park J; Kim SH; Lee SW; Park HA; Ha M; Choi KH
    Clin Chem Lab Med; 2011 Mar; 49(3):527-34. PubMed ID: 21320028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.